Biotechnology company Nona Biosciences announced Thursday a research collaboration with Atossa Therapeutics Inc. (ATOS). The collaboration leverages Nona's proprietary H2L2 Harbour Mice platform to identify next-generation therapeutic candidates for breast cancer.
Nona Biosciences' proprietary Harbour Mice platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization.
Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and accelerating drug discovery and development.
To date, Harbour Mice platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas and has been widely recognized by global partners.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.